{"id":"https://openalex.org/W2531840703","doi":"https://doi.org/10.1080/14656566.2016.1244529","title":"Update on pharmacotherapy for treatment of opioid use disorder","display_name":"Update on pharmacotherapy for treatment of opioid use disorder","alternate_titles":[],"publication_year":2016,"publication_date":"2016-10-20","ids":{"openalex":"https://openalex.org/W2531840703","doi":"https://doi.org/10.1080/14656566.2016.1244529","mag":"2531840703","pmid":"https://pubmed.ncbi.nlm.nih.gov/27734745"},"language":"en","primary_location":{"id":"doi:10.1080/14656566.2016.1244529","doi":"https://doi.org/10.1080/14656566.2016.1244529","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14656566.2016.1244529","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2531840703"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049992187","display_name":"Daniel Ayanga","orcid":"https://orcid.org/0000-0002-2116-5467","observed_orcids":["https://orcid.org/0000-0002-2116-5467"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Daniel Ayanga","raw_affiliation_strings":["a Menninger Department of Psychiatry and Behavioral Sciences , Baylor College of Medicine , Houston , TX , USA","Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Menninger Department of Psychiatry and Behavioral Sciences , Baylor College of Medicine , Houston , TX , USA","institution_ids":["https://openalex.org/I181547552"]},{"raw_affiliation_string":"Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA","institution_ids":["https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033847683","display_name":"Daryl I. Shorter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299501804","display_name":"Michael E. DeBakey VA Medical Center","ror":"https://ror.org/052qqbc08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299501804","https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210138636"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Daryl Shorter","raw_affiliation_strings":["b Research Service Line, Michael E. DeBakey VA Medical Center, Menninger Department of Psychiatry and Behavioral Sciences , Baylor College of Medicine , Houston , TX , USA","Research Service Line, Michael E. DeBakey VA Medical Center, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"b Research Service Line, Michael E. DeBakey VA Medical Center, Menninger Department of Psychiatry and Behavioral Sciences , Baylor College of Medicine , Houston , TX , USA","institution_ids":["https://openalex.org/I1299501804","https://openalex.org/I181547552"]},{"raw_affiliation_string":"Research Service Line, Michael E. DeBakey VA Medical Center, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA","institution_ids":["https://openalex.org/I1299501804","https://openalex.org/I181547552"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071214414","display_name":"Thomas R. Kosten","orcid":"https://orcid.org/0000-0003-1505-555X","observed_orcids":["https://orcid.org/0000-0003-1505-555X"]},"institutions":[{"id":"https://openalex.org/I1299501804","display_name":"Michael E. DeBakey VA Medical Center","ror":"https://ror.org/052qqbc08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299501804","https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210138636"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomas R. Kosten","raw_affiliation_strings":["c Departments of Psychiatry; Neuroscience; Pharmacology; Immunology & Pathology , Baylor College of Medicine, Michael E. DeBakey VA Medical Center , Houston , TX , USA","Departments of Psychiatry","Immunology & Pathology, Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX, USA","Neuroscience","Pharmacology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"c Departments of Psychiatry; Neuroscience; Pharmacology; Immunology & Pathology , Baylor College of Medicine, Michael E. DeBakey VA Medical Center , Houston , TX , USA","institution_ids":["https://openalex.org/I1299501804","https://openalex.org/I181547552"]},{"raw_affiliation_string":"Departments of Psychiatry","institution_ids":[]},{"raw_affiliation_string":"Immunology & Pathology, Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1299501804","https://openalex.org/I181547552"]},{"raw_affiliation_string":"Neuroscience","institution_ids":[]},{"raw_affiliation_string":"Pharmacology","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5033847683"],"corresponding_institution_ids":["https://openalex.org/I1299501804","https://openalex.org/I181547552"],"apc_list":null,"apc_paid":null,"fwci":1.0447,"has_fulltext":false,"cited_by_count":88,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.73818788,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"17","issue":"17","first_page":"2307","last_page":"2318"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11199","display_name":"Pain Management and Opioid Use","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/opioid-use-disorder","display_name":"opioid use disorder","score":1.0},{"id":"https://openalex.org/keywords/drug-therapy","display_name":"pharmacotherapy","score":0.9399999976158142},{"id":"https://openalex.org/keywords/opioid-withdrawal","display_name":"opioid withdrawal","score":0.5370000004768372},{"id":"https://openalex.org/keywords/opioid-maintenance-treatment","display_name":"opioid maintenance treatment","score":0.628000020980835},{"id":"https://openalex.org/keywords/methadone","display_name":"methadone","score":0.9229999780654907},{"id":"https://openalex.org/keywords/buprenorphine","display_name":"buprenorphine","score":1.0},{"id":"https://openalex.org/keywords/naltrexone","display_name":"naltrexone","score":0.8980000019073486},{"id":"https://openalex.org/keywords/clonidine","display_name":"clonidine","score":0.9459999799728394},{"id":"https://openalex.org/keywords/alpha-2-adrenergic-agonists","display_name":"alpha-2 adrenergic agonists","score":0.9660000205039978},{"id":"https://openalex.org/keywords/mu-opioid-receptor-agonists","display_name":"mu-opioid receptor agonists","score":0.7139999866485596},{"id":"https://openalex.org/keywords/opioid-antagonists","display_name":"opioid antagonists","score":0.7620000243186951}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.899817943572998},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.7572413682937622},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.5077100992202759},{"id":"https://openalex.org/C2779418921","wikidata":"https://www.wikidata.org/wiki/Q1639178","display_name":"Opioid use disorder","level":4,"score":0.48899757862091064},{"id":"https://openalex.org/C2777972943","wikidata":"https://www.wikidata.org/wiki/Q409587","display_name":"Naltrexone","level":4,"score":0.46344971656799316},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4390186369419098},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.395863801240921},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3419680595397949},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2919301390647888},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003000","descriptor_name":"Clonidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003000","descriptor_name":"Clonidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008691","descriptor_name":"Methadone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008691","descriptor_name":"Methadone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D009293","descriptor_name":"Opioid-Related Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058647","descriptor_name":"Adrenergic alpha-2 Receptor Agonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D058647","descriptor_name":"Adrenergic alpha-2 Receptor Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D058850","descriptor_name":"Opiate Substitution Treatment","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/14656566.2016.1244529","doi":"https://doi.org/10.1080/14656566.2016.1244529","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14656566.2016.1244529","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:27734745","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27734745","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9907000064849854,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3998877375","display_name":null,"funder_award_id":"IK2 CX000946","funder_id":"https://openalex.org/F4320306127","funder_display_name":"U.S. Department of Veterans Affairs"},{"id":"https://openalex.org/G6435555080","display_name":"Stimulant Pharmacotherapy: Noradrenergic Targets","funder_award_id":"P50DA018197","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320306127","display_name":"U.S. Department of Veterans Affairs","ror":"https://ror.org/05rsv9s98"},{"id":"https://openalex.org/F4320309037","display_name":"Office of Research and Development","ror":"https://ror.org/05rsv9s98"},{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":109,"referenced_works":["https://openalex.org/W117895865","https://openalex.org/W142954314","https://openalex.org/W282431559","https://openalex.org/W1041456650","https://openalex.org/W1516008423","https://openalex.org/W1577485982","https://openalex.org/W1702336527","https://openalex.org/W1713077592","https://openalex.org/W1822999396","https://openalex.org/W1839254548","https://openalex.org/W1876353446","https://openalex.org/W1897292339","https://openalex.org/W1929735328","https://openalex.org/W1941462008","https://openalex.org/W1965331149","https://openalex.org/W1968500528","https://openalex.org/W1968733353","https://openalex.org/W1969614457","https://openalex.org/W1974538875","https://openalex.org/W1974944903","https://openalex.org/W1978922105","https://openalex.org/W1982769895","https://openalex.org/W1983167472","https://openalex.org/W1983749649","https://openalex.org/W1984615306","https://openalex.org/W1984945428","https://openalex.org/W1988125188","https://openalex.org/W1988132987","https://openalex.org/W1989126239","https://openalex.org/W1990290956","https://openalex.org/W1995916748","https://openalex.org/W1998720265","https://openalex.org/W2000388826","https://openalex.org/W2000500216","https://openalex.org/W2003035491","https://openalex.org/W2005728294","https://openalex.org/W2010468128","https://openalex.org/W2016298461","https://openalex.org/W2017177786","https://openalex.org/W2021011301","https://openalex.org/W2022312732","https://openalex.org/W2024033047","https://openalex.org/W2025988777","https://openalex.org/W2026092210","https://openalex.org/W2027583644","https://openalex.org/W2027984744","https://openalex.org/W2030996161","https://openalex.org/W2032952768","https://openalex.org/W2033024456","https://openalex.org/W2038011254","https://openalex.org/W2043129776","https://openalex.org/W2044502637","https://openalex.org/W2048236414","https://openalex.org/W2051226969","https://openalex.org/W2061007797","https://openalex.org/W2061505471","https://openalex.org/W2061946344","https://openalex.org/W2065431063","https://openalex.org/W2069177552","https://openalex.org/W2074570011","https://openalex.org/W2078979610","https://openalex.org/W2081296862","https://openalex.org/W2084970765","https://openalex.org/W2089549038","https://openalex.org/W2089653975","https://openalex.org/W2091187494","https://openalex.org/W2095384014","https://openalex.org/W2100607375","https://openalex.org/W2103464480","https://openalex.org/W2108492482","https://openalex.org/W2108664899","https://openalex.org/W2111173132","https://openalex.org/W2113204404","https://openalex.org/W2116946309","https://openalex.org/W2121189426","https://openalex.org/W2124486489","https://openalex.org/W2126437722","https://openalex.org/W2127186356","https://openalex.org/W2129362339","https://openalex.org/W2132974770","https://openalex.org/W2134732195","https://openalex.org/W2135387265","https://openalex.org/W2142847270","https://openalex.org/W2143468987","https://openalex.org/W2145366493","https://openalex.org/W2149999684","https://openalex.org/W2152872602","https://openalex.org/W2153653527","https://openalex.org/W2153716482","https://openalex.org/W2157091279","https://openalex.org/W2159121584","https://openalex.org/W2159870164","https://openalex.org/W2162028386","https://openalex.org/W2162792128","https://openalex.org/W2164000900","https://openalex.org/W2164953375","https://openalex.org/W2165230254","https://openalex.org/W2168594794","https://openalex.org/W2168922064","https://openalex.org/W2170684975","https://openalex.org/W2171008207","https://openalex.org/W2172107654","https://openalex.org/W2270666457","https://openalex.org/W2300149049","https://openalex.org/W2327042539","https://openalex.org/W2407406545","https://openalex.org/W4210849799","https://openalex.org/W4213392178","https://openalex.org/W4247665917"],"related_works":["https://openalex.org/W4410414333","https://openalex.org/W2150270654","https://openalex.org/W2094015709","https://openalex.org/W2963093289","https://openalex.org/W2773341134","https://openalex.org/W4288640018","https://openalex.org/W4312061797","https://openalex.org/W1983107997","https://openalex.org/W2025339047","https://openalex.org/W4399418718"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Opioid":[1,111],"Use":[2],"Disorder":[3],"(OUD)":[4],"is":[5,115,156,173,197],"a":[6,45],"significant":[7],"public":[8],"health":[9],"concern,":[10],"negatively":[11],"impacting":[12],"the":[13,101,106,129,169],"medical,":[14],"psychological,":[15],"and":[16,40,105,127,132,140,155,190],"social":[17],"domains":[18],"of":[19,38,48,150,157,179],"an":[20,174],"individual's":[21],"life":[22],"as":[23,25,64,66,81,83,86,96,98,100,134,136],"well":[24,65,82,99,135],"creating":[26],"substantial":[27],"burdens":[28],"for":[29,36,58,148,177],"society.":[30],"Effective":[31],"treatment":[32,113,149,163,188],"interventions":[33],"are":[34],"necessary":[35],"reduction":[37],"OUD":[39,59,151],"its":[41],"consequences.":[42],"Pharmacotherapy":[43],"represents":[44],"central":[46],"component":[47],"management.":[49],"Areas":[50],"covered:":[51],"This":[52],"review":[53],"focuses":[54],"on":[55,119],"pharmacologic":[56],"strategies":[57],"treatment,":[60],"discussing":[61],"both":[62,73],"primary":[63],"adjunctive":[67],"therapy":[68,147,182,196],"modalities.":[69],"We":[70],"will":[71],"discuss":[72],"medications":[74,90,121],"used":[75,85],"during":[76],"detoxification":[77],"to":[78,123],"treat":[79],"withdrawal,":[80],"those":[84,120],"maintenance":[87,112],"therapy.":[88],"Detox":[89],"include":[91],"alpha-2":[92],"adrenergic":[93],"agonists,":[94,130],"such":[95],"clonidine,":[97],"\u03bc-opioid":[102,107],"agonist,":[103,109],"methadone,":[104],"partial":[108],"buprenorphine.":[110],"(OMT)":[114],"also":[116],"discussed,":[117],"focusing":[118],"meant":[122],"substitute":[124],"abused":[125],"opioids":[126],"includes":[128],"methadone":[131,165],"buprenorphine,":[133],"supervised":[137],"intravenous":[138],"heroin,":[139],"opioid":[141],"antagonist,":[142],"naltrexone.":[143,184],"Expert":[144],"opinion:":[145],"Medication":[146],"has":[152],"demonstrated":[153],"efficacy":[154],"great":[158],"clinical":[159],"benefit.":[160],"While":[161],"agonist":[162],"with":[164,183],"or":[166],"buprenorphine":[167],"remains":[168],"gold":[170],"standard,":[171],"there":[172],"important":[175],"place":[176],"use":[178],"long-acting":[180],"antagonist":[181],"Continued":[185],"investigation":[186],"into":[187],"paradigms":[189],"behavioral":[191],"platforms":[192],"which":[193],"optimize":[194],"medication":[195],"most":[198],"needed.":[199]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2531840703","counts_by_year":[{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":14},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-10-21T00:00:00"}
